Меню
Идёт набор NCT06837194

Washed Microbiota Transplantation Combined With Enteral Nutrition for Gastroptosis

Наблюдательное Gastroptosis Malnutrition

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
Это наблюдательное исследование: исследуемое лечение участникам по протоколу не назначают.
Кому может быть актуально
Состояния в реестре: Gastroptosis, Malnutrition. Базовые параметры: 18 лет — 100 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Китай
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Официальное название

The Efficacy of WMT Combined With Nutritional Support in the Treatment of Malnutrition Complicated by Gastroptosis: A Real-World Study

Обзор

This is a observational study to explore the efficacy and safety of washed microbiota transplantation (WMT) combined with nutritional support for gastroptosis patients

Первичные конечные точки

  • The proportion of gastroptosis with degree relief after the procedure. [Срок оценки: baseline, 12 weeks post transplantation]
Вторичные конечные точки (12)
  • change of the third lumbar vertebrae skeletal muscle mass and height [Срок оценки: baseline, 12 weeks post transplantation]
  • change of weight and height [Срок оценки: baseline, 4 weeks, 8 weeks, 12 weeks post transplantation]
  • change of the Gastrointestinal Symptom Rating Scale(GSRS) [Срок оценки: baseline, 4 weeks, 8 weeks, 12 weeks post transplantation]
  • The extent of change observed in Gastroparesis Cardinal Symptom Index(GCSI)of participants [Срок оценки: baseline, 4 weeks, 8 weeks, 12 weeks post transplantation]
  • The results of gastric fitted emptying rate data for 2 hours or 4 hours in the gastric emptying experiment with nuclide imaging [Срок оценки: baseline, 12 weeks post transplantation]
  • change of the 5-level EuroQoL Group's 5-dimension (EQ-5D-5L) [Срок оценки: baseline, 4 weeks, 8 weeks, 12 weeks post transplantation]
  • change of the Pittsburgh Sleep Quality Index (PSQI) [Срок оценки: baseline, 4 weeks, 8 weeks, 12 weeks post transplantation]
  • change of the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) [Срок оценки: baseline, 4 weeks, 8 weeks, 12 weeks post transplantation]
  • The extent of change observed in gastrointestinal ultrasound (GIUS) of participants [Срок оценки: baseline, 12 weeks post transplantation]
  • The extent of change observed in transcranial Doppler (TCD) of participants [Срок оценки: baseline, 12 weeks post transplantation]
  • change of the Hamilton Anxiety Scale(HAMA) [Срок оценки: baseline, 4 weeks, 8 weeks, 12 weeks post transplantation]
  • change of the Hamilton Depression Scale(HAMD) [Срок оценки: baseline, 4 weeks, 8 weeks, 12 weeks post transplantation]

Критерии участия

Критерии включения

  • Subjects must meet all of the following inclusion criteria to enter the study:
  • Clinically diagnosed with gastroptosis;
  • Meets the diagnostic criteria for malnutrition (fulfilling any one of the following two criteria):
  • Weight loss (weight loss >5% within the last 6 months or >10% over more than 6 months);
  • Low BMI (BMI <18.5 kg/m² for individuals <70 years old; BMI <20 kg/m² for individuals ≥70 years old);
  • Males aged ≥18 years and non-pregnant, non-lactating females aged ≥18 years;
  • Willing to voluntarily sign a written informed consent form and agrees to follow medical advice for regular follow-up examinations and monitoring after the completion of treatment.

Критерии исключения

  • Subjects meeting any of the following exclusion criteria must be excluded from the study:
  • Patients with severe depression, anxiety, or cognitive impairment that affects normal physician-patient communication and treatment planning;
  • Patients with poor compliance who cannot accept treatment regimens such as nasogastric enteral nutrition;
  • Anticipated survival time <3 months;
  • Clinically significant cardiovascular diseases, including heart failure (NYHA Class III-IV), uncontrolled coronary artery disease, cardiomyopathy, arrhythmia, history of myocardial infarction, hemodynamic instability at enrollment, unstable vital signs, or anticipated risk events during treatment;
  • Poor pulmonary function deemed by investigators to impact study treatment (e.g., acute exacerbation of COPD or requirement for long-term oral/intravenous corticosteroids \[excluding inhaled corticosteroids\]);
  • Active severe clinical infections (> Grade 2 per NCI-CTCAE v5.0), including patients with intestinal fungal, viral, or tuberculosis infections;
  • Inability to cooperate with intestinal tube placement or contraindications to intestinal tube placement;
  • Use of medications affecting or modulating gut microbiota within the past 48 hours;
  • Lack of legal capacity or restricted legal capacity;
  • Hematologic disorders unsuitable for blood draw examinations;
  • Other severe medical conditions deemed by investigators to preclude patient enrollment.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Модель наблюдения
Когортное

Центры проведения

Китай · 1 центр
  • Department of Microbiota Medicine & Medical Centre for Digestive Diseases, The Second Affi — Нанкин

Публикации

  • Zhang F, Cui B, He X, Nie Y, Wu K, Fan D; FMT-standardization Study Group. Microbiota transplantation: concept, methodology and strategy for its modernization. Protein Cell. 2018 May;9(5):462-473. doi: 10.1007/s13238-018-0541-8. Epub 2018 Apr 24. PMID 29691757
  • Quince C, Ijaz UZ, Loman N, Eren AM, Saulnier D, Russell J, Haig SJ, Calus ST, Quick J, Barclay A, Bertz M, Blaut M, Hansen R, McGrogan P, Russell RK, Edwards CA, Gerasimidis K. Extensive Modulation of the Fecal Metagenome in Children With Crohn's Disease During Exclusive Enteral Nutrition. Am J Gastroenterol. 2015 Dec;110(12):1718-29; quiz 1730. doi: 10.1038/ajg.2015.357. Epub 2015 Nov 3. PMID 26526081
  • Fernandes ND, Murphy SA. Gastroptosis: An Uncommon Cause for a Deep Nasogastric Tube. Clin Gastroenterol Hepatol. 2021 Jun;19(6):A23. doi: 10.1016/j.cgh.2020.04.016. Epub 2020 Apr 11. No abstract available. PMID 32289543
  • Xu LC, Garcia JC. Gastroptosis in a young woman. Gastrointest Endosc. 2024 Mar;99(3):454-455. doi: 10.1016/j.gie.2023.10.006. Epub 2023 Oct 5. No abstract available. PMID 37804872
  • Peng Z, Xiang J, He Z, Zhang T, Xu L, Cui B, Li P, Huang G, Ji G, Nie Y, Wu K, Fan D, Zhang F. Colonic transendoscopic enteral tubing: A novel way of transplanting fecal microbiota. Endosc Int Open. 2016 Jun;4(6):E610-3. doi: 10.1055/s-0042-105205. Epub 2016 Apr 28. PMID 27556065
  • Xiang L, Yu Y, Ding X, Zhang H, Wen Q, Cui B, Zhang F. Exclusive Enteral Nutrition Plus Immediate vs. Delayed Washed Microbiota Transplantation in Crohn's Disease With Malnutrition: A Randomized Pilot Study. Front Med (Lausanne). 2021 Oct 22;8:666062. doi: 10.3389/fmed.2021.666062. eCollection 2021. PMID 34746161

Идентификаторы

NCT: NCT06837194 · WMT-gastroptosis

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗